Evaluation of Responsive Gene Expression as a Sensitive and Specific Biomarker in Patients with Ulcerative Colitis

Background:Clinical trials in ulcerative colitis (UC) rely on certain parameters to evaluate responses that are highly subjective or of low sensitivity. Here, using a select group of genes, we tested the accuracy of gene expression analysis as a biomarker of clinical, endoscopic, and histologic improvements. Methods:Intestinal biopsies were obtained from UC patients included in two cohorts. Cohort 1 was used to select for genes whose expression was modulated in active (vs. inactive) UC. Cohort 2 included patients recruited in a phase II study receiving placebo, mesalazine, or dersalazine sodium for 4 weeks. The expression of 44 genes identified in Cohort 1 was assessed at weeks 0 and 4, and was then correlated with biomarkers, as well as with clinical, endoscopic, and histologic scores. Results:Significant changes in the expression of 31 of the 44 genes tested were detected in Cohort 2 at week 4. Gene expression (&Dgr;Ct) significantly correlated with the total Mayo score, C-reactive protein (CRP), and fecal calprotectin. The number of genes significantly regulated at week 4 was highly associated with histologic and endoscopic responses. Logistic regression analysis identified four separate genes (IFITM1, ITGB2, IL1R2, IL2RA) whose relative change was independently associated with endoscopic remission with high specificity and sensitivity. Conclusions:Change in the expression of a select set of genes can serve as an early biomarker, one with high specificity and sensitivity to clinical, endoscopic, and histologic responses. This could represent a new tool for identifying early response to treatment in mild to moderately active UC patients.

[1]  P. Rutgeerts,et al.  Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis. , 2011, Gastroenterology.

[2]  J. Llach,et al.  Narrow-band imaging as an alternative to chromoendoscopy for the detection of dysplasia in long-standing inflammatory bowel disease: a prospective, randomized, crossover study. , 2011, Gastrointestinal endoscopy.

[3]  P. Moayyedi,et al.  An Evidence-Based Systematic Review on Medical Therapies for Inflammatory Bowel Disease , 2011, The American Journal of Gastroenterology.

[4]  P. Rutgeerts,et al.  Mucosal Gene Expression of Cell Adhesion Molecules, Chemokines, and Chemokine Receptors in Patients With Inflammatory Bowel Disease Before and After Infliximab Treatment , 2011, The American Journal of Gastroenterology.

[5]  P. Higgins,et al.  Value of mucosal assessment and biomarkers in inflammatory bowel disease , 2010, Expert review of gastroenterology & hepatology.

[6]  S. Gallus,et al.  Are Colonoscopy and Bowel Ultrasound Useful for Assessing Response to Short-Term Therapy and Predicting Disease Outcome of Moderate-to-Severe Forms of Ulcerative Colitis?: A Prospective Study , 2010, The American Journal of Gastroenterology.

[7]  A. Kornbluth,et al.  Ulcerative Colitis Practice Guidelines in Adults: American College of Gastroenterology, Practice Parameters Committee , 2010, The American Journal of Gastroenterology.

[8]  M. Abreu,et al.  Biological markers in inflammatory bowel disease: practical consideration for clinicians. , 2009, Gastroenterologie clinique et biologique.

[9]  M. Vatn,et al.  Clinical course during the first 10 years of ulcerative colitis: results from a population-based inception cohort (IBSEN Study) , 2009, Scandinavian journal of gastroenterology.

[10]  Jack Satsangi,et al.  Regional variation in gene expression in the healthy colon is dysregulated in ulcerative colitis , 2008, Gut.

[11]  Paul Rutgeerts,et al.  Infliximab for induction and maintenance therapy for ulcerative colitis. , 2005, The New England journal of medicine.

[12]  A. Zinsmeister,et al.  Correlation of C‐Reactive Protein With Clinical, Endoscopic, Histologic, and Radiographic Activity in Inflammatory Bowel Disease , 2005, Inflammatory bowel diseases.

[13]  Thomas Lengauer,et al.  Dissection of the Inflammatory Bowel Disease Transcriptome Using Genome-Wide cDNA Microarrays , 2005, PLoS medicine.

[14]  T. Endo,et al.  Inflammatory gene signature in ulcerative colitis with cDNA macroarray analysis , 2005, Alimentary pharmacology & therapeutics.

[15]  F. S. de Medina,et al.  The Intestinal Anti-inflammatory Activity of UR-12746S on Reactivated Experimental Colitis Is Mediated Through Downregulation of Cytokine Production , 2003, Inflammatory bowel diseases.

[16]  F. Speleman,et al.  Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes , 2002, Genome Biology.

[17]  I. Lawrance,et al.  Ulcerative colitis and Crohn's disease: distinctive gene expression profiles and novel susceptibility candidate genes. , 2001, Human molecular genetics.

[18]  A. Öst,et al.  A reproducible grading scale for histological assessment of inflammation in ulcerative colitis , 2000, Gut.

[19]  A. Zarzuelo,et al.  Intestinal anti‐inflammatory activity of UR‐12746, a novel 5‐ASA conjugate, on acute and chronic experimental colitis in the rat , 2000, British journal of pharmacology.

[20]  S. Rosewicz,et al.  Differential expression of matrix metalloproteinases and their tissue inhibitors in colon mucosa of patients with inflammatory bowel disease , 2000, Gut.

[21]  M. Cheang,et al.  Quantification of the placebo response in ulcerative colitis. , 1997, Gastroenterology.

[22]  S. Riley,et al.  Microscopic activity in ulcerative colitis: what does it mean? , 1991, Gut.

[23]  R. Wright,et al.  Serial rectal biopsy in ulcerative colitis during the course of a controlled therapeutic trial of various diets , 1966, The American Journal of Digestive Diseases.

[24]  A. Kornbluth,et al.  Ulcerative colitis practice guidelines in adults , 1997 .